Ex vivo dual gene therapy using human adipocytes secreting anti-HER2 antibody on HER2-positive xenograft tumor models

被引:0
作者
Ryotaro Teranaka
Hiroshi Fujimoto
Takahito Masuda
Masayuki Kuroda
Yasuyuki Aoyagi
Takeshi Nagashima
Mamoru Takada
Junta Sakakibara
Hideyuki Yamada
Hiroto Yamamoto
Yoshitaka Kubota
Masayuki Ohtsuka
机构
[1] Chiba University Graduate School of Medicine,Department of General Surgery
[2] Chiba University Hospital,Center for Advanced Medicine
[3] CellGenTech,Department of Plastic, Reconstructive, and Aesthetic Surgery
[4] Inc.,undefined
[5] Chiba University Graduate School of Medicine,undefined
来源
Breast Cancer | 2023年 / 30卷
关键词
Breast cancer; Adipocytes; Gene therapy; Human epidermal growth factor receptor 2; Molecular target therapy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1018 / 1027
页数:9
相关论文
共 50 条
[41]   HER2-positive breast cancer, how far away from the cure?-on the current situation of anti-HER2 therapy in breast cancer treatment and survival of patients [J].
Liao, Ning .
CHINESE CLINICAL ONCOLOGY, 2016, 5 (03)
[42]   Therapeutic potential of a novel IP-10-(anti-HER2 scFv) fusion protein for the treatment of HER2-positive breast cancer [J].
Maryam Ahmadzadeh ;
Elham Mohit .
Biotechnology Letters, 2023, 45 :371-385
[43]   Therapeutic potential of a novel IP-10-(anti-HER2 scFv) fusion protein for the treatment of HER2-positive breast cancer [J].
Ahmadzadeh, Maryam ;
Mohit, Elham .
BIOTECHNOLOGY LETTERS, 2023, 45 (03) :371-385
[44]   Tumor-targeted gene delivery via anti-HER2 antibody (trastuzumab, Herceptin®) conjugated polyethylemmine [J].
Chiu, SH ;
Ueno, NT ;
Lee, RJ .
JOURNAL OF CONTROLLED RELEASE, 2004, 97 (02) :357-369
[45]   HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study [J].
Samia kada Mohammed ;
Oumar Billa ;
Sylvain Ladoire ;
Clementine Jankowski ;
Isabelle Desmoulins ;
Marie-Laure Poillot ;
Charles Coutant ;
Françoise Beltjens ;
Sandrine Dabakuyo ;
Laurent Arnould .
Breast Cancer, 2023, 30 :343-353
[46]   HER2-positive invasive lobular carcinoma: a rare breast cancer which may not necessarily require anti-HER2 therapy. A population-based study [J].
Mohammed, Samia Kada ;
Billa, Oumar ;
Ladoire, Sylvain ;
Jankowski, Clementine ;
Desmoulins, Isabelle ;
Poillot, Marie-Laure ;
Coutant, Charles ;
Beltjens, Francoise ;
Dabakuyo, Sandrine ;
Arnould, Laurent .
BREAST CANCER, 2023, 30 (03) :343-353
[47]   Relative efficacy of antibody-drug conjugates and other anti-HER2 treatments on survival in HER2-positive advanced breast cancer: a systematic review and meta-analysis [J].
Kang, Zian ;
Jin, Yuqing ;
Yu, Huihui ;
Li, Su ;
Qi, Yingjie .
BMC CANCER, 2024, 24 (01)
[48]   MNX1 Promotes Anti-HER2 Therapy Sensitivity via Transcriptional Regulation of CD-M6PR in HER2-Positive Breast Cancer [J].
Chi, Weiru ;
Xiu, Bingqiu ;
Xiong, Min ;
Wang, Xuliren ;
Li, Pei ;
Zhang, Qi ;
Hou, Jianjing ;
Sang, Yuting ;
Zhou, Xujie ;
Chen, Ming ;
Zheng, Shuyue ;
Zhang, Liyi ;
Xue, Jingyan ;
Chi, Yayun ;
Wu, Jiong .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (01)
[49]   Using in vivo fluorescence lifetime imaging to detect HER2-positive tumors [J].
Ardeshirpour, Yasaman ;
Sackett, Dan L. ;
Knutson, Jay R. ;
Gandjbakhche, Amir H. .
EJNMMI RESEARCH, 2018, 8
[50]   Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients [J].
Arslan, U. Y. ;
Turker, I. ;
Aksoy, S. ;
Oksuzoglu, B. ;
Helvaci, K. ;
Ozdemir, N. Yildirim ;
Uyeturk, U. ;
Sonmez, O. Uysal ;
Budakoglu, B. ;
Zengin, N. .
JOURNAL OF BUON, 2013, 18 (03) :585-593